Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was downgraded by Sanford C. Bernstein from a “market perform” rating to an “underperform” rating in a report released on Wednesday, MarketBeat reports. They currently have a $8.30 price target on the stock, down from their prior price target of $11.90. Sanford C. Bernstein‘s price objective would indicate a potential downside of 22.21% from the stock’s previous close.
A number of other equities analysts also recently commented on the company. Summit Redstone set a $25.00 price objective on Summit Therapeutics in a research report on Wednesday, September 9th. HC Wainwright reaffirmed a “buy” rating on shares of Summit Therapeutics in a report on Thursday, October 15th. Morgan Stanley downgraded shares of Summit Therapeutics to an “outperform” rating in a research note on Tuesday, September 29th. Wall Street Zen upgraded shares of Summit Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 5th. Finally, Citigroup lowered their price target on shares of Summit Therapeutics from $43.00 to $42.00 and set a “buy” rating for the company in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $28.10.
Read Our Latest Research Report on Summit Therapeutics
Summit Therapeutics Stock Performance
Shares of NASDAQ SMMT opened at $10.67 on Wednesday. The stock’s 50-day moving average is $16.16 and its two-hundred day moving average is $16.09. Summit Therapeutics has a 1-year low of $10.53 and a 1-year high of $29.23.
Institutional Trading of Summit Therapeutics
A number of institutional investors have recently bought and sold shares of SMMT. Fifth Third Bancorp lifted its holdings in shares of Summit Therapeutics by 24.4% during the first quarter. Fifth Third Bancorp now owns 3,732 shares of the company’s stock worth $71,000 after purchasing an additional 732 shares during the period. Tidal Investments LLC grew its position in Summit Therapeutics by 0.7% in the 2nd quarter. Tidal Investments LLC now owns 121,097 shares of the company’s stock valued at $1,764,000 after buying an additional 783 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Summit Therapeutics by 2.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 42,714 shares of the company’s stock valued at $722,000 after buying an additional 1,021 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Summit Therapeutics by 1.1% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 95,254 shares of the company’s stock valued at $1,611,000 after buying an additional 1,025 shares during the period. Finally, GAMMA Investing LLC increased its stake in Summit Therapeutics by 61.7% in the 3rd quarter. GAMMA Investing LLC now owns 2,697 shares of the company’s stock valued at $46,000 after buying an additional 1,029 shares during the period. 4.61% of the stock is owned by hedge funds and other institutional investors.
About Summit Therapeutics
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Further Reading
- Five stocks we like better than Summit Therapeutics
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
